Mink Therapeutics Inc INKT.OQ INKT.O is expected to report results on November 14 for the period ending September 30 2024
LSEG's mean analyst estimate for Mink Therapeutics Inc is for a loss of 8 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Mink Therapeutics Inc is 8.00, above its last closing price of $0.75.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jan. 1 0001 | -0.10 | -0.10 | -0.07 | Beat | 30 |
Mar. 31 0001 | -0.16 | -0.15 | -0.11 | Beat | 28.3 |
Dec. 31 2023 | -0.15 | -0.16 | Missed | -4.3 | |
Sep. 30 2023 | -0.18 | -0.18 | -0.15 | Beat | 17.8 |
Jun. 30 2023 | -0.19 | -0.20 | -0.18 | Beat | 8.9 |
Mar. 31 2023 | -0.25 | -0.24 | -0.17 | Beat | 28.4 |
Jan. 1 0001 | -0.21 | -0.23 | Missed | -9.5 | |
Sep. 30 2022 | -0.23 | -0.23 | -0.19 | Beat | 18.3 |
This summary was machine generated November 12 at 14:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。